References
- Kim K, Kim W S, Jung C W, Im Y H, Kang W K, Lee M H, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38: 75–81
- Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo J M, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849–855
- DeCoteau J F, Kadin M E. New insights into peripheral T-cell lymphomas. Curr Opin Oncol 1995; 7: 408–414
- Ko Y -H, Kim C -W, Park C -S, Jang H K, Lee S S, Kim S H, , For the Hematolymphoreticular Study Group of the Korean Society of Pathologists, et al. REAL classification of malignant lymphomas in the Republic of Korea. Cancer 1998; 83: 806–812
- Cabanillas F, Hagemeister F B, Bodey G P, Freireich E J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
- Huijgens P C, Ossenkoppele G J, Van Der Lelie J, Thomas L L, Wijngaarden M J, Slaper C M. IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma. Hematol Oncol 1991; 9: 245–251
- Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002; 68: 354–361
- Cheson B D, Horning S J, Coiffier B, Shipp Ma, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
- Lee K W, Kim D W, Im S A, Kim T Y, Yoon S S, Heo D S, et al. Efficacy of ifosfamide, methotrexate, etoposide and prednisone (IMEP) chemotherapy in extranodal NK/T-cell lymphoma, nasal type. ASCO Annual Meeting 2004, Abstract no. 6685.
- Rodriguez J, Munsell M, Yazji S, Hagemeister F B, Younes A, Andersson B, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770
- Rodriguez J, Caballero M D, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372–1377
- Au W Y, Lie A K, Liang R, Kwong Y L, Yau C C, Cheung M M, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673–1676
- Jantunen E, D'Amore F. Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma 2004; 45: 441–446
- Kahl C, Leithauser M, Wolff D, Steiner B, Hartung G, Casper J, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 2002; 81: 646–650
- Song K W, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985
- Kim W S, Song S Y, Ahn Y C, Ko Y H, Baek C H, Kim D Y, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 2001; 12: 349–352